Note: This image contains AI-generated elements.
Kevin Lobo will give up Stryker's CEO title on December 31 and keep a CEO's salary and bonus target.
Stryker's board promoted Spencer Stiles, President and Chief Operating Officer (COO), to CEO effective January 1, 2027. He ran Orthopaedics from 2019. On capital allocation, he has held Stryker's enterprise acquisition strategy since 2019. The strategy and mergers and acquisitions brief has been his as COO since January 2026, under a CEO credited with setting the direction. On setting that direction himself, the record is not yet his.
On the person, J.P. Morgan called Stiles 'up to the task'. On the process, Truist called the transition low-risk on October 6. It also cut its price target that day over what management said at September investor conferences. Shares closed October 6 at $278.20, down 2.46%, and October 7 at $275.40, level with their October 2 close.
Lobo will become Executive Chair. His letter agreement keeps his $1.55 million salary and $2.325 million bonus target and ends new stock awards. It names no end date and no duties. Sherilyn McCoy, Lead Independent Director, signed it. And from January, two of eleven directors will be executives.
Stiles will inherit a recovery from a cyber incident first reported March 11 and a supply shortfall at the Inari peripheral vascular unit. Both are operating challenges, where his record is deepest. An executive chair paid a CEO salary may steady him or blur who decides.
At Eagle Talon we weigh Lobo's pay against his written remit, Stiles's fit to the recovery, and the board's independence from both.
I expect the board to put an end date on the Executive Chair role within a year, by filing or in the 2027 proxy. If Lobo is still Executive Chair on unchanged pay with no stated end date at the end of 2028, I misjudged the arrangement.
What does Stryker's board still need an executive chair to decide that its CEO cannot?
🔗 Source: Stryker Announces Leadership Succession
